ICAM1 and neoplasm: As human LFA-1 I domain exhibits reactivity with both murine and human ICAM-128 at comparable affinities, we were able to preclinically address potency against human tumors overexpressing ICAM-1 and simultaneously monitor potential on-target, off-tumor systemic toxicity against normal mouse tissues expressing murine ICAM-1.